Search

everythinglearnresearchcommunity

for

Search:↓

Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.

Frozen-thawed fibroblast sheets enhance wound healing and hair growth in mice.

Black hairy tongue can be an early sign of graft-versus-host disease after stem cell transplants.

Older age is the main risk factor for hemorrhagic cystitis after stem cell transplants.

A man developed facial skin lesions after a stem cell transplant, which improved with specific treatments.

A five-month-old boy with Omenn syndrome successfully recovered after a stem cell transplant with reduced intensity conditioning.

Older age and prostatic hyperplasia in males increase the risk of hemorrhagic cystitis after stem cell transplantation.

Amotosalen-treated donor T-cells can prevent late CMV infection after bone marrow transplants.

CMV infection increases the risk of GvHD after bone marrow transplants.

Person-to-person hair transplants can work for patients on lifelong immunosuppression, with high hair growth success.

Some children who had stem cell transplants developed permanent hair loss, especially when treated with a drug called busulphan.

Chemotherapy and bone marrow transplant can cause permanent hair loss.

Adipose-derived stem cells are promising for regenerative medicine due to their accessibility, versatility, and low risk of immune rejection.

Topical treatments and skin care improve transplant-related atopic dermatitis in children.

FTY720 helps transplanted fat survive better by reducing immune rejection and improving blood vessel growth.

A woman's sudden hair loss three years after a bone marrow transplant was a sign of chronic graft-versus-host disease but improved with treatment.

Graft-versus-host disease is a complication where donor immune cells attack the recipient's body, often affecting the skin, liver, and gastrointestinal tract.

People with allergies or high eosinophil levels have a higher chance of severe hair loss from alopecia areata, and sudden hair loss can indicate chronic graft-versus-host disease.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.

Patients with GATA2 deficiency show early skin symptoms that help diagnose the condition.

Permanent hair loss after a stem cell transplant can be a sign of chronic immune system attack on the scalp.

Folliculotropic mycosis fungoides has a worse prognosis than other types, with survival rates varying significantly based on subtype and organ involvement.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

Mitochondrial therapy and platelet-rich plasma therapy both stimulated hair regrowth in aging mice, with mitochondrial therapy showing similar effectiveness to plasma therapy.

Busulfan/cyclophosphamide and total bone irradiation are equally effective for AML transplants.

Combining UVB irradiation and anti-CD154 antibody improves hair follicle transplant survival.

Graft-versus-host disease occurs when donor immune cells attack the recipient's body, causing skin, gut, and liver damage.

Skin issues from chronic graft-versus-host disease greatly affect daily life, needing teamwork between blood and skin doctors.

Somatostatin helps hair follicles suppress immune responses, which might aid in treating certain hair loss conditions.

Stem cell therapy is promising for treating various health conditions, but more research is needed to understand its full potential and address challenges.